QVA149 significantly reduced the rate of moderate to severe exacerbations versus glycopyrronium by 12 % ( annualised rate of exacerbations 084 [ 95 % CI 075-094 ] vs 095 [ 085-106 ] ; rate ratio 088 , 95 % CI 077-099 , p = 0038 ) .